Mectronic

SINUVA[™] (mometasone furoate) sinus implant payer coverage

* As of 8/25/2022

Disclaimer

Medtronic provides this information for your convenience only. It does not constitute legal advice or a recommendation regarding clinical practice. Information provided is gathered from third-party sources and is subject to change without notice due to frequently changing laws, rules and regulations. The provider has the responsibility to determine medical necessity and to submit appropriate codes and charges for the care provided. Medtronic makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other payers as to the correct form of billing or the amount that will be paid to providers of service. Please contact your Medicare contractor, other payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage and payment policies. This document provides assistance for FDA approved or cleared indications. Where reimbursement is sought for use of a product that may be inconsistent with, or not expressly specified in, the FDA cleared or approved labeling (e.g. instructions for use, operator's manual or package insert), consult with your billing advisors or payers on handling such billing issues. Some payers may have policies that make it inappropriate to submit claims for such items or related service.

Individual payer plans may vary. Contracted rates for Buy & Bill will vary.

Payers covering SINUVA sinus implant under the medical/pharmacy benefit

(Prior authorization may be necessary)

Commercial Payer Coverage

- Aetna, Inc.
- Avera
- Blue Cross and Blue Shield of Florida, Inc.
- Blue Cross Blue Shield of Kansas
- Blue Cross Blue Shield of South Carolina
- Blue Cross of Idaho Health Servce Inc
- Capital District Physicians Health Plan, Inc.
- CareFirst BCBS
- Dean Health System
- Emblem Health
- Federal Employee BCBS (FEP)
- Geisinger Health System Corporation
- Hawaii Medical Service Association (HMSA)
- Health Alliance Plan HAP (Henry Ford Health System)
- Health Care Service Corporation (BCBS TX, BCBS IL, BCBS, OK, BCBS NM, BCBS MT)

- Health New England, Inc.
- Health Plan of Nevada (HPN)
- HealthFirst (FL)
- HealthNet
- HealthPartners, Inc.
- Highmark, Inc.
- Humana, Inc.
- Kaiser Foundation Health Plans, Inc.
- Medica Health Plans
- Moda Health
- MVP Health Care, Inc.
- Network Health
- PacificSource Health Plan
- Prime Therapeutics
- Providence Health SystemQuartz Health Solutions
- Quartz Health Solutions (Wisconsin)
- UnitedHealth Group, Inc.
- UPMC Health System

- Federal and State Health Plan Coverage
 CalOptima
 Natio
- CareSource Management Group
- Centene Corporation
- CGS Administrators, LLC MAC
- Commonwealth of Puerto Rico
- ConnectiCare
- DakotaCare
- Department of Defense -TRICARE
- Department of Veterans Affairs (VHA)
- Fallon Community Health Plan, Inc.
- Federal BCBS (FEP)
- Fidelis Care New York
- First Coast Service Options, Inc. MAC
- Gateway Health Plan
- Healthfirst NY
- Humana Medicare
- Inland Empire Health Plan
- Magellan Rx Management
- Medi-Cal
- Molina Health Care, Inc.

- National Government Services, Inc MAC
- Neighborhood Health Plan of Rhode Island
- Noridian Healthcare Solutions, LLC MAC
- Novitas Solutions, Inc MAC
- Palmetto GBA, LLC MAC
- State of California Medi-CAL
- State of Connecticut
- State of Florida
- State of Georgia
- State of Massachusetts
- State of Michigan
- State of Montana
- State of Nevada
- State of New York
- State of North Carolina
- State of North Dakota
- State of Oklahoma
- State of Vermont
- State of Washington
- UCare Minnesota, Inc.
- Wisconsin Physicians Service Insurance WPS MAC

Please see Important Safety Information on the following page.

Welcome to personalized patient support

Connect offers high-quality support to assist your patients in navigating the insurance approval and acquisition process for SINUVA™ (mometasone furoate) sinus implant.

Support includes:

- A simplified patient enrollment form
- Dedicated Case Managers
- Timely benefits investigation (BI)
- Comprehensive prior authorization communication
- Appeals support until a decision is made
- Coordinated reimbursement support services
- Product acquisition and distribution support

Call Connect directly at:

1-833-4-SINUVA (1-833-474-6882) Monday - Friday, 8 AM - 8 PM ET or visit <u>SINUVA.com/hcp/ordering</u> Connect Dedicated experts. Dependable resources. Insightful solutions.

Connect representatives are available to assist your patients and your office in obtaining SINUVA.

1-833-4-SINUVA (1-833-474-6882) Monday - Friday, 8 AM - 8 PM ET

To verify your patient's individual coverage for SINUVA, fax the Patient Enrollment form to 844-745-2358. The Enrollment Form can also be found at <u>SINUVA.com/patient-enrollment.pdf</u>

Indication

SINUVA Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients \geq 18 years of age who have had ethmoid sinus surgery.

Important safety information contraindications

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.

Warnings and precautions

Local effects: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

Ocular effects: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

Hypersensitivity reactions: Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

Immunosuppression: Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

Hypercorticism and adrenal suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

Adverse reactions

The most common adverse reactions observed (> 1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

Postmarketing experience

The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.

Rx only. Please see attached Full Prescribing Information for SINUVA also available at SINUVA.com/PI.



ENT

6743 Southpoint Drive N Jacksonville, FL 32216 USA Toll free: (800) 874-5797 Telephone: (904) 296-9600 Fax: (800) 678-3995